ADT |
Androgen-deprivation therapy |
4EBP1 |
4E (eIF4E)-binding protein 1 |
AMO |
Antisense anti-miR oligonucleotide |
AR |
Androgen receptor |
BER |
Base excision repair |
BRCA1 |
Breast cancer susceptibility protein 1 |
BRCA2 |
Breast cancer susceptibility protein 2 |
C2D |
C2 domain |
Cas9 |
CRISPR-associated protein 9, |
CHK1 |
Cyclin D1 and checkpoint kinase 1 |
cIAP-1 |
Cellular inhibitor of apoptosis protein-1 |
CRISPR |
Clustered regularly interspaced short palindromic repeat |
CRPC |
Castrate-resistant prostate cancer |
CTC |
Circulating tumor cell |
CXCL8 |
C-X-C motif chemokine ligand 8, interleukin 8 |
DDR |
DNA damage response |
DEPTOR |
Disheveled, EGL-10 and pleckstrin (DEP) domain-containing mTOR-interacting protein |
DHT |
Dihydrotestosterone |
DRE |
Digital rectal examination |
DSBs |
Double-strand breaks |
EGFR |
Epidermal growth factor receptor |
EMT |
Epithelial-to-mesenchymal transition |
ECM |
Extracellular matrix |
FISH |
Fluorescence in situ hybridization |
FOXO |
Forkhead box protein O |
GAS6 |
Growth arrest-specific protein 6 |
GSK3β |
Glycogen synthase kinase 3 beta |
GPCR |
G-protein coupled receptor |
HER2 |
Human epidermal growth factor receptor 2 |
HRR |
Homologous recombination repair |
IHC |
Immunohistochemistry |
IL6 |
Interleukin 6 |
IL8 |
Interleukin 8 |
ITSN |
Intersectin |
LNA |
Locked nucleic acid |
MAN2C1 |
α-mannosidase 2C1 |
MAPK |
Mitogen-activated protein kinase |
MAPKAP1 |
Mammalian stress-activated protein kinase-interacting protein 1 |
mCRPC |
Metastatic castrate-resistant prostate cancer |
MDSC |
Myeloid-derived suppressor cells |
MEF |
Mouse embryonic fibroblast |
miRNA |
Micro ribonucleic acid |
mHSPC |
Metastatic hormone-sensitive prostate cancer |
mLST8 |
Mammalian lethal with SEC13 protein 8 |
MMR |
Mismatch repair |
mpMRI |
Multiparametric MRI |
mTOR |
Mammalian target of rapamycin |
mTORC1 |
Mammalian target of rapamycin complex 1 |
mTORC2 |
Mammalian target of rapamycin complex 2 |
NER |
Nucleotide excision repair |
NF-κB |
Nuclear factor kappa light chain enhancer of activated B cells |
NHEJ |
Non-homologous end joining |
NSCLC |
Non-small-cell lung carcinoma |
OncomiRs |
Oncogenic miRNAs |
P |
Phosphorylation event |
PBD |
PIP2-binding domain |
PARP |
Poly-ADP ribose polymerase |
PDK1 |
Phosphoinositide-dependent kinase 1 |
PH domain |
Pleckstrin homology domain |
Phos D |
Phosphatase domain |
PI3K |
Phosphoinositide 3-kinase |
PIP2 |
Phosphatidylinositol 4,5-bisphosphate |
PIP3 |
Phosphatidylinositol 3,4,5-trisphosphate |
PKB |
Protein kinase B, AKT |
PKC |
Protein kinase C |
PKCε |
Protein kinase C epsilon |
PKCζ |
Protein kinase C zeta |
PRAS40 |
Proline-rich AKT substrate of 40 kDa |
PREX1 |
PIP3-dependent Rac exchanger 1 |
PREX2 |
PIP3-dependent Rac exchanger 2 |
PSA |
Prostate-specific antigen |
PTEN |
Phosphatase and tensin homologue deleted on chromosome 10 |
RAPTOR |
Regulatory-associated protein of mTOR |
RBD |
Ras-binding domain |
RHEB |
Ras homolog enriched in brain |
RICTOR |
Rapamycin-insensitive companion of mTOR |
rPFS |
Radiographic progression-free survival |
RFS |
Recurrence-free survival |
RTK |
Tyrosine kinase receptor |
S6K |
Ribosomal protein S6 kinase/p70 ribosomal S6 kinase |
SGK1 |
Serum- and glucocorticoid-regulated kinase 1 |
SGK2 |
Serum- and glucocorticoid-regulated kinase 2 |
SGK3 |
Serum- and glucocorticoid-regulated kinase 3 |
siRNA |
Small interfering RNA |
SMIR |
Small-molecule inhibitors of miRNA |
SRC-3 |
Steroid receptor co-activator 3 |
SSBs |
Single-strand breaks |
TAM |
Tumor-associated macrophage |
TSC1 |
Tuberous sclerosis complex 1 |
TSC2 |
Tuberous sclerosis complex 2 |
TSIs |
Tumor–stroma interactions |
VAV3 |
Vav guanine nucleotide exchange factor 3 |